Navigation Links
LF Elimination Program Treats Over Half Billion People and Protects Millions More From Debilitating Disease
Date:10/7/2008

120 million people in 83 countries are currently infected.

The Global Program to Eliminate LF has already become the most rapidly scaled-up drug administration program in public health history, and is on track to becoming the largest such program in history. The study found that since drug administrations began in 2000, the program has administered more than 1.9 billion treatments to over 570 million people in 48 of the 83 countries with endemic LF.

The LF elimination treatment program utilizes a combination of two anti-parasitic drugs, administered once yearly to everyone in an at-risk area. When given for a minimum of five consecutive years, these drugs can effectively stop transmission of LF. The drugs used to eliminate LF are the same medications used to treat a number of intestinal worms and parasitic skin diseases, which infect hundreds of millions of people in developing countries and are major contributors to malnutrition, disability, delayed development, and problems during pregnancy.

"The benefits of this program go far beyond simply preventing LF infections," said Dr. Eric A. Ottesen, MD, Director of the Atlanta Lymphatic Filariasis Support Center and lead author of the paper. "Because of the LF program, at least 56.6 million children and 44.5 million women of childbearing age have been treated for intestinal worms, most multiple times. The drugs have also treated millions more in Africa for skin diseases."

These data help the PLoS paper confirm what some public health officials have long asserted: that the LF program is the 'best buy' in public health, providing benefits that far outweigh its costs. The total cost per patient over the first eight years of the program is estimated to be less than US $0.50. This low cost is made possible in part by the donation of albendazole and Mectizan(R) from the program's two key pharmaceutical partners GlaxoSmithKline and Merck & Co., Inc.

The cost-efficiency combined with the prog
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Zimmer Holdings Announces Support for Elimination of Super-Majority Voting Requirements
2. Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program
3. Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
4. Stem Cell Transplantation Program at Hackensack University Medical Center: First in Nation to Receive Joint Commission Certification for Quality and First in New Jersey to be Named a Blue Distinction(R) Center for Specialty Care.
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
7. UCB Scholarship Program Awards $300,000 to Students Living with Crohns Disease
8. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
9. KGI Offers Mammalian Cell Culture Program for Biotech Industry Professionals
10. Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
11. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Wyeth,Pharmaceuticals, a division of Wyeth (NYSE: WYE ... the 63rd Annual Meeting of the American Society ... 100 mg/day or,150 mg/day of desvenlafaxine, a serotonin ... in moderate to severe,vasomotor symptoms (VMS) (hot flashes ...
... Cellmark Inc.,(Nasdaq: ORCH ), a leading worldwide ... third quarter 2007 financial results on,Thursday, November 1, ... hosting a,conference call and webcast to discuss the ... Management will discuss financial results for the third ...
... Technique to be Presented at American ... Meeting -, - Improved Techniques Could Lead to ... well as PGD with In Vitro Fertilization -, ... developing high throughput technologies that enable genome-wide,analyses, and Reprogenetics, ...
Cached Biology Technology:Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo 2Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo 3Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo 4Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo 5Orchid Cellmark to Announce Third Quarter 2007 Financial Results on November 1, 2007 2Empire Genomics and Reprogenetics Join Forces to Improve Preimplantation Genetic Diagnosis (PGD) 2Empire Genomics and Reprogenetics Join Forces to Improve Preimplantation Genetic Diagnosis (PGD) 3
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research ... announced the addition of the "Global Facial ... http://photos.prnewswire.com/prnh/20130307/600769 ... the identification of individuals. Facial recognition system measures ... as nose, jaw edges, mouth, and the distance ...
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... 9, 2014  Valencell, a leader in performance biometric ... staggering demand from its licensees for highly accurate, clinically ... not solely coming from fitness and health sectors, but ... "A wearable is only as useful as the biometric ... ultimate driver in long-term mass consumer adoption of wearable ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... A new study by the Wildlife Conservation Society, ... that habitat fragmentation and the addition of makeshift perches ... preferred habitat for common ravens that threaten sensitive ... The study appears in the January issue of the ...
... Renewable Energy Laboratory (NREL) have discovered that an enzyme from ... the Kamchatka Peninsula in Russia in 1990 can digest cellulose ... enzyme on the market. If the enzyme continues to ... the price of making lignocellulosic fuels, from ethanol to other ...
... 2014 -- Although drugs have been developed that inhibit the ... which causes many brain disorders and nervous system diseases ... work has not yet been fully explained. Now, ... as a model, have deciphered the mode by which the ...
Cached Biology News:Might more ravens -- aided by humans -- mean 'nevermore' for sage-grouse? 2Might more ravens -- aided by humans -- mean 'nevermore' for sage-grouse? 3NREL finds a new cellulose digestion mechanism by a fast-eating enzyme 2NREL finds a new cellulose digestion mechanism by a fast-eating enzyme 3Neurotransmitters resarch can promote better drugs for brain disorders 2Neurotransmitters resarch can promote better drugs for brain disorders 3
...
...
SphingoStripsTM contain fifteen different biologically active, nitrocellulose-immobilized lipids at 100 pmol per spot, which can be assayed for protein binding and specificity using a simple blot ove...
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The version upgrade allows upgrade of an established version of...
Biology Products: